UCB SA (OTCMKTS:UCBJY) Short Interest Down 57.1% in September

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 3,300 shares, a decline of 57.1% from the September 15th total of 7,700 shares. Based on an average daily trading volume, of 64,700 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 64,700 shares, the days-to-cover ratio is presently 0.1 days.

UCB Trading Up 1.2%

UCBJY opened at $147.76 on Tuesday. The business’s fifty day moving average is $127.02 and its two-hundred day moving average is $104.85. UCB has a one year low of $71.16 and a one year high of $151.76.

Wall Street Analyst Weigh In

UCBJY has been the topic of a number of analyst reports. The Goldman Sachs Group upgraded UCB to a “strong-buy” rating in a research note on Wednesday, July 16th. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 29th. Two analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, UCB has a consensus rating of “Strong Buy”.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.